Immunome Research
Open Access
ISSN: 1745-7580
+44-77-2385-9429
ISSN: 1745-7580
+44-77-2385-9429
Department of Clinical Microbiology, Tanlun Research Institute for Clinical Management of Cancer, Beijing, China
Review Article
The Blocking vs. Depletion Model of Immune Checkpoint Inhibitor Therapy for Cancer
Author(s): Kangla Tsung*, Zhang Xu and Zhanghui
Immune Checkpoint Inhibitor (ICI) therapy is the most exciting development in cancer treatments in recent years. As of the end of 2021, more than a hundred of clinical trials have been carried out by several major drug makers and research hospitals all over the world just to explore the use of ICI antibodies in almost every type of cancer and under various clinical settings. These clinical trials have resulted waves of good news in every year’s major academic conferences and FDA approvals, and now ICI therapy is in the move to take over traditional therapy to become the major player in clinical management of cancer. On the other hand, most of these clinical trials have failed to show clear benefits in most cancer patients, and only few have been reported in public. In real-world clinical setting, ICI antibodies are being massively and sometimes abusively prescribed for almost ev.. View More»
DOI:
DOI: 10.35248/1745-7580.22.18.157